Bristol-myers Squibb Compnay

David S Yoon

Alicia Regueiro-Ren

Chunjian Liu

Jeffrey A Robl

Wei Meng

Shoshana L Posy

Ramesh Kumar Sistla

Shung C Wu

Susheel Jethanand Nara

Bruce A Ellsworth

Satheesh Kesavan Nair

Jacob Swidorski

Guohua Zhao

Richard A Hartz

Gang Wu

Andrew P Degnan

Peter T W Cheng

Yanting Huang

Manoranjan Panda

Srinivas Cheruku

Brett R Beno

Prasada Rao Jalagam

Wei Wang

Jianxin Feng

Li Xu

Elizabeth Anne Jurica

Rushith Kumar Anumula

Ximao Wu

Rishikesh Narayan

Michael Mandler

Peter TW Cheng

The present invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.

Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors

The present invention provides compounds of Formula (I): 

Bridged bicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and Rare defined herein. 

Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Growing community of inventors

Yardley, PA, United States of America

David S Yoon